Should You Buy Piramal Pharma After Its Strong Q1 FY27 Results?

About This Analysis

Piramal Pharma delivered an impressive first quarter of FY27, with revenue and profitability significantly exceeding Goldman Sachs' expectations. Broad-based growth across all three business segments, improving operating leverage and management's confident outlook for FY27 reinforce the company's long-term growth story. Goldman Sachs continues to view Piramal Pharma as one of the attractive opportunities within the pharmaceutical sector.

Goldman Sachs Maintains Buy Rating

Goldman Sachs has maintained its Buy recommendation on Piramal Pharma with a target price of ₹250. The brokerage highlighted:

• Revenue and EBITDA significantly exceeded expectations.
• Strong operational execution across all business divisions.
• Healthy margin expansion supported by operating leverage.

Looking For Daily Stock Market Opportunities?

👉 Latest Nifty Tips

Stay updated with expert market analysis, pharmaceutical sector insights and investment opportunities.

Strong Financial Performance

Piramal Pharma reported a strong start to FY27. Key highlights include:

• Revenue increased 17% year-on-year.
• EBITDA surged 83% year-on-year.
• Both revenue and EBITDA were meaningfully ahead of Goldman Sachs' estimates and market consensus.

The strong performance was driven by healthy growth across all three operating segments.

CDMO Business Continues To Perform Well

The Contract Development and Manufacturing Organisation (CDMO) business remained a major growth driver. Key segment performance:

• CDMO revenue: Up 19% year-on-year.
• Complex Hospital Generics (CHG): Up 17% year-on-year.
• India Consumer Healthcare (ICH): Up 15% year-on-year.

Goldman Sachs noted that both the CDMO and CHG businesses outperformed its estimates, while ICH broadly met expectations.

Follow Daily Bank Nifty & Market Updates

👉 Latest BankNifty Tips

Read expert analysis covering pharmaceuticals, healthcare and market-moving sectors.

Margin Expansion Driven By Operating Leverage

Profitability improved significantly during the quarter. Key highlights include:

• EBITDA margin expanded to 8.6%.
• Margin improved by 308 basis points year-on-year.
• Margin exceeded Goldman Sachs' estimate by 135 basis points.

The improvement reflects stronger operating leverage as higher revenue translated into faster profit growth.

Management Outlook Remains Positive

Following the completion of inventory destocking in its largest CDMO product during FY26, management reaffirmed its guidance. For FY27, the company expects:

• Low- to mid-teen revenue growth.
• EBITDA growth faster than revenue growth.
• PAT growth to outpace revenue growth.

Management also reiterated its long-term aspiration to achieve:

• US$2 billion in annual revenue by FY30.
• 25% EBITDA margin by FY30.

These targets reflect confidence in the company's long-term expansion strategy.

Investor Takeaway

Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, who is also a SEBI Registered Investment Adviser, observes that Piramal Pharma has delivered a strong quarter with broad-based growth across its CDMO, CHG and Consumer Healthcare businesses. Improving operating leverage, expanding margins and management's confidence in achieving faster earnings growth reinforce the company's long-term investment story. Investors should continue monitoring CDMO demand, execution of growth initiatives and progress toward the FY30 revenue and margin targets.

Read Free market insights at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.

Written by Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.

Disclaimer: This article is intended solely for educational and informational purposes. Brokerage opinions represent the views of the respective research firms and may differ significantly. This article should not be construed as investment advice or a recommendation to buy or sell any security. Investors should conduct their own research or consult a SEBI Registered Investment Adviser before making investment decisions.